ApoE polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM?

被引:41
作者
Boize, R
Benhamou, PY
Corticelli, P
Valenti, K
Bosson, JL
Halimi, S
机构
[1] Univ Hosp, Dept Endocrinol, Grenoble, France
[2] Univ Hosp, Dept Biochem, Grenoble, France
[3] Univ Hosp, Dept Biomath, Grenoble, France
关键词
apolipoprotein E; coronaropathy; microalbuminuria; diabetic nephropathy; NIDDM;
D O I
10.1093/ndt/13.1.72
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Chronic hyperglycaemia stands with diabetes duration as the main predicting factor for the development of nephropathy in insulin dependent diabetes mellitus (IDDM). In contrast, nephropathy in non-insulin-dependent diabetes mellitus (NIDDM) presents with a different natural history and, as well as atherosclerosis, can precede diabetes diagnosis and even the onset of patent hyperglycaemia. The role of lipid abnormalities in this matter remains debated. Methods. We studied the prevalence of nephropathy (N+ = urinary albumin excretion rate (UAE) > 20 mg/d) in 134 Caucasian NIDDM patients ranked according to alipoprotein E (apoE) genotype (same distribution in 132 controls). Age, diabetes duration and sex ratio did not differ between N+ and N-. A patient with E2E4 (n=1) was excluded from the analysis. Results. The prevalence of nephropathy was significantly reduced in E2 allele carriers (36%, 8/22) vs 69% (77/111) in E2 non-carriers (P<0.01). Relative risk (RR) of E2 carriers developing nephropathy was 0.52 (95% CI=0.35-0.80). Both groups were comparable in terms of age (55+/-11 vs 57+/-11 years), diabetes duration (15+/-9 vs 14+/-10 years) and prevalence of retinopathy (59 vs 48%). Similar results were observed when patients with diabetes duration longer than 8 years were studied (n=94). Conclusions. It has been largely established that low-density lipoprotein (LDL)-cholesterol level in E2 allele carriers (whether diabetic or not) was lower than in E2 non-carriers. The 2-fold increase of nephropathy in E2 non-carriers with NIDDM argues for a role for LDL in the development of human nephropathy in NIDDM patients. This result is in agreement with previous data established both in vitro and in vivo in animal models. These findings support evidence for the pathogenic and morphologic similarities between kidney disease and atherosclerosis in NIDDM patients.
引用
收藏
页码:72 / 75
页数:4
相关论文
共 22 条
  • [1] APOLIPOPROTEIN-E POLYMORPHISM AS A RISK FACTOR FOR VASCULAR-DISEASE IN DIABETIC-PATIENTS
    BOEMI, M
    SIROLLA, C
    AMADIO, L
    FUMELLI, P
    POMETTA, D
    JAMES, RW
    [J]. DIABETES CARE, 1995, 18 (04) : 504 - 508
  • [2] APOLIPOPROTEIN-E POLYMORPHISM AND ATHEROSCLEROSIS
    DAVIGNON, J
    GREGG, RE
    SING, CF
    [J]. ARTERIOSCLEROSIS, 1988, 8 (01): : 1 - 21
  • [3] APOLIPOPROTEIN-E POLYMORPHISM AFFECTS PLASMA-LEVELS OF LIPOPROTEIN(A)
    DEKNIJFF, P
    KAPTEIN, A
    BOOMSMA, D
    PRINCEN, HMG
    FRANTS, RR
    HAVEKES, LM
    [J]. ATHEROSCLEROSIS, 1991, 90 (2-3) : 169 - 174
  • [4] FOCAL AND SEGMENTAL GLOMERULOSCLEROSIS - ANALOGIES TO ATHEROSCLEROSIS
    DIAMOND, JR
    KARNOVSKY, MJ
    [J]. KIDNEY INTERNATIONAL, 1988, 33 (05) : 917 - 924
  • [5] GABELLI C, 1995, ATHEROSCLEROSIS, V109, P241
  • [6] Gavin JR, 1997, DIABETES CARE, V20, P1183
  • [7] THE ROLE OF LIPIDS IN NEPHROSCLEROSIS AND GLOMERULOSCLEROSIS
    GRONE, EF
    WALLI, AK
    GRONE, HJ
    MILLER, B
    SEIDEL, D
    [J]. ATHEROSCLEROSIS, 1994, 107 (01) : 1 - 13
  • [8] GRONE HJ, 1989, LAB INVEST, V60, P433
  • [9] ONSET OF NIDDM OCCURS AT LEAST 4-7 YR BEFORE CLINICAL-DIAGNOSIS
    HARRIS, MI
    KLEIN, R
    WELBORN, TA
    KNUIMAN, MW
    [J]. DIABETES CARE, 1992, 15 (07) : 815 - 819
  • [10] HIXSON JE, 1990, J LIPID RES, V31, P545